Skip to main content

Advertisement

SpringerLink
Log in

Clinical and histopathological predictors of outcome in malignant meningioma

  • Original Article
  • Published:
Neurosurgical Review Aims and scope Submit manuscript

Abstract

We investigated possible clinical and histopathological prognostic factors in a malignant meningioma cohort with comprehensive long-term population-based follow-up data. Twenty-four consecutive patients treated surgically for malignant meningioma at the Department of Neurosurgery and the Department of Pathology, Rigshospitalet, Copenhagen, Denmark, from December 2000 to March 2014 were retrospectively evaluated regarding progression-free survival (PFS) and overall survival (OS). Clinical parameters were recorded. All specimens underwent immunohistochemical analysis for Ki-67 and phosphohistone-H3 (PHH3). Prognostication was assessed with Cox proportional hazard regression analysis. The median follow-up was 46.1 months (range 0.7–150.7). The median progression-free survival was 16.5 months (95% CI 11.4–43.0) and the median overall survival was 46.6 months (95% CI 20.4–NA). Six patients were alive at the end of follow-up; two of these had not experienced a recurrence. No clinical parameter showed significant association with PFS or OS. Mitotic index (MI) was significantly associated with PFS and OS, and PHH3 MI with PFS. Immunohistochemical reactivity of Ki-67 > 10% was a negative predictor of PFS (HR 3.92, 95% CI 1.47–10.4, p = 0.0063) and OS (HR 3.35, 95% CI 1.12–10.1, p = 0.0313). The histological subgrouping of grade III meningioma into anaplastic and non-anaplastic revealed increased PFS for the latter (HR 4.57, CI 95% 1.32–15.7, p = 0.0164). We could not verify previous clinical parameters as prognostic factors in malignant meningioma. MI and the PHH3 MI were prognostic within WHO grade III meningiomas for PFS. An overall tumor staining of Ki-67 > 10% correlated with PFS and OS within grade III tumors.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Abry E, Thomassen IT, Salvesen ØO, Torp SH (2010) The significance of Ki-67/MIB-1 labeling index in human meningiomas: a literature study. Pathol Res Pract 206:810–815. https://doi.org/10.1016/j.prp.2010.09.002

    Article  CAS  PubMed  Google Scholar 

  2. Adeberg S, Hartmann C, Welzel T, Rieken S, Habermehl D, von Deimling A, Combs SE (2012) Long-term outcome after radiotherapy in patients with atypical and malignant meningiomas d clinical results in 85 patients treated in a single institution leading to optimized guidelines for early radiation therapy. 83. https://doi.org/10.1016/j.ijrobp.2011.08.010

  3. Balasubramanian SK, Sharma M, Silva D, Karivedu V, Schmitt P, Stevens GH, Barnett GH, Prayson RA, Elson P, Suh JH, Murphy ES, Chao ST (2017) Longitudinal experience with WHO grade III (anaplastic) meningiomas at a single institution. J Neuro-Oncol 131:555–563. https://doi.org/10.1007/s11060-016-2321-8

    Article  Google Scholar 

  4. Baxter DS, Orrego A, Rosenfeld JV, Mathiesen T (2014) An audit of immunohistochemical marker patterns in meningioma. J Clin Neurosci 21:421–426. https://doi.org/10.1016/j.jocn.2013.06.008

    Article  CAS  PubMed  Google Scholar 

  5. Bi WL, Zhang M, Wu WW, Mei Y, Dunn IF (2016) Meningioma genomics: diagnostic, prognostic, and therapeutic applications. Front Surg 3:1–7. https://doi.org/10.3389/fsurg.2016.00040

    Article  Google Scholar 

  6. Bruna J, Brell M, Ferrer I, Gimenez-Bonafe P, Tortosa A (2007) Ki-67 proliferative index predicts clinical outcome in patients with atypical or anaplastic meningioma. Neuropathology 27:114–120. https://doi.org/10.1111/j.1440-1789.2007.00750.x

    Article  PubMed  Google Scholar 

  7. Champeaux C, Wilson E, Brandner S, Shieff C, Thorne L (2015) World Health Organization grade III meningiomas. A retrospective study for outcome and prognostic factors assessment. Br J Neurosurg 29:693–698. https://doi.org/10.3109/02688697.2015.1054350

    Article  PubMed  Google Scholar 

  8. Claus EB, Bondy ML, Schildkraut JM, Wiemels JL, Wrensch M, Black PM (2005) Epidemiology of intracranial meningioma. Neurosurgery 57:1088–1095

    Article  Google Scholar 

  9. Durand A, Labrousse F, Jouvet A, Bauchet L, Kalamaridès M, Menei P, Deruty R, Moreau JJ, Fèvre-Montange M, Guyotat J (2009) WHO grade II and III meningiomas: a study of prognostic factors. J Neuro-Oncol 95:367–375. https://doi.org/10.1007/s11060-009-9934-0

    Article  Google Scholar 

  10. Duregon E, Cassenti A, Pittaro A, Ventura L, Senetta R, Rudà R, Cassoni P (2015) Better see to better agree: phosphohistone H3 increases interobserver agreement in mitotic count for meningioma grading and imposes new specific thresholds. Neuro-Oncology 17:663–669. https://doi.org/10.1093/neuonc/nov002

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Ehresman JS, Garzon-Muvdi T, Rogers D, Lim M, Gallia GL, Weingart J, Brem H, Bettegowda C, Chaichana KL (2018) The relevance of Simpson grade resections in modern neurosurgical treatment of World Health Organization grade I, II, and III meningiomas. World Neurosurg 109:e588–e593. https://doi.org/10.1016/j.wneu.2017.10.028

    Article  PubMed  Google Scholar 

  12. Fathi A-R, Roelcke U (2013) Meningioma. Curr Neurol Neurosci Rep 13:337. https://doi.org/10.1007/s11910-013-0337-4

    Article  CAS  PubMed  Google Scholar 

  13. Fukushima S, Terasaki M, Sakata K, Miyagi N, Kato S, Sugita Y, Shigemori M (2009) Sensitivity and usefulness of anti-phosphohistone-H3 antibody immunostaining for counting mitotic figures in meningioma cases. Brain Tumor Pathol 26:51–57. https://doi.org/10.1007/s10014-009-0249-9

    Article  PubMed  Google Scholar 

  14. Gerring Z, Pearson JF, Morrin HR, Robinson BA, Harris GC, Walker LC (2015) Phosphohistone H3 outperforms Ki67 as a marker of outcome for breast cancer patients. Histopathology 67:538–547. https://doi.org/10.1111/his.12678

    Article  PubMed  Google Scholar 

  15. Hua L, Zhu H, Li J, Tang H, Kuang D (2017) Prognostic value of estrogen receptor in WHO grade III meningioma: a long-term follow-up study from a single institution. 1–9. https://doi.org/10.3171/2017.2.JNS162566

  16. Hwang KL, Hwang WL, Bussière MR, Shih HA (2017) The role of radiotherapy in the management of high-grade meningiomas. Chin Clin Oncol 6:S5. https://doi.org/10.21037/cco.2017.06.09

    Article  PubMed  Google Scholar 

  17. Iwasaki T, Matsushita M, Nonaka D, Kato M, Nagata K, Murakami I, Hayashi K (2015) Phosphohistone-H3 (PHH3) is prognostic relevant in Merkel cell carcinomas but Merkel cell polyomavirus is a more powerful prognostic factor than AJCC clinical stage, PHH3, Ki-67 or mitotic indices. Pathol Int 65:404–409. https://doi.org/10.1111/pin.12305

    Article  CAS  PubMed  Google Scholar 

  18. Kaley T, Barani I, Chamberlain M, McDermott M, Panageas K, Raizer J, Rogers L, Schiff D, Vogelbaum M, Weber D, Wen P (2014) Historical benchmarks for medical therapy trials in surgery- and radiation-refractory meningioma: a RANO review. Neuro-Oncology 16:829–840. https://doi.org/10.1093/neuonc/not330

    Article  PubMed  PubMed Central  Google Scholar 

  19. Katz LM, Hielscher T, Liechty B, Silverman J, Zagzag D, Sen R, Wu P, Golfinos JG, Reuss D, Neidert MC, Wirsching H-G, Baumgarten P, Herold-Mende C, Wick W, Harter PN, Weller M, von Deimling A, Snuderl M, Sen C, Sahm F (2018) Loss of histone H3K27me3 identifies a subset of meningiomas with increased risk of recurrence. Acta Neuropathol 135:955–963. https://doi.org/10.1007/s00401-018-1844-9

    Article  CAS  PubMed  Google Scholar 

  20. Kaur G, Sayegh ET, Larson A, Bloch O, Madden M, Sun MZ, Barani IJ, James CD, Parsa AT (2014) Adjuvant radiotherapy for atypical and malignant meningiomas: a systematic review. Neuro-Oncology 16:628–636. https://doi.org/10.1093/neuonc/nou025

    Article  PubMed  PubMed Central  Google Scholar 

  21. Kim YJ, Ketter R, Steudel WI, Feiden W (2007) Prognostic significance of the mitotic index using the mitosis marker anti-phosphohistone H3 in meningiomas. Am J Clin Pathol 128:118–125. https://doi.org/10.1309/HXUNAG34B3CEFDU8

    Article  CAS  PubMed  Google Scholar 

  22. Kim J-K, Tae-Young J, Shin J, Kyung-Hwa L, Seul-Kee K, Eun Jung L (2016) Meningiomas with rhabdoid or papillary components : prognosis and comparison with anaplastic meningiomas. Korean Neurosurg Soc 59:357–362. https://doi.org/10.3340/jkns.2016.59.4.357

    Article  CAS  Google Scholar 

  23. Lim YS, Kim MK, Park BJ, Kim TS, Lim YJ (2013) Long term clinical outcomes of malignant meningiomas. Brain Tumor Res Treat 1:85–90. https://doi.org/10.14791/btrt.2013.1.2.85

    Article  PubMed  PubMed Central  Google Scholar 

  24. Louis, DN (2016) WHO classification of tumours of the central nervous system. International Agency for Research on Cancer, France

  25. Louis D, Ohgaki H, Wiestler O, Cavenee W (2016) WHO classification of tumours of the central nervous system, 4th edn. International Agency for Research on Cancer, World Health Organization, Lyon

    Google Scholar 

  26. Moliterno J, Cope WP, Vartanian ED, Reiner AS, Kellen R, Ogilvie SQ, Huse JT, Gutin PH (2015) Survival in patients treated for anaplastic meningioma. J Neurosurg 123:23–30. https://doi.org/10.3171/2014.10.jns14502

    Article  PubMed  Google Scholar 

  27. Olar A, Wani KM, Sulman EP, Mansouri A, Zadeh G, Wilson CD, Demonte F, Fuller GN, Aldape KD (2015) Mitotic index is an independent predictor of recurrence-free survival in meningioma. Brain Pathol 25:266–275. https://doi.org/10.1111/bpa.12174

    Article  PubMed  Google Scholar 

  28. Ozturk Sari S, Taskin OC, Gundogdu G, Yegen G, Onder S, Keskin M, Saglam S, Ozluk Y, Gulluoglu M, Mete O (2016) The impact of phosphohistone-H3-assisted mitotic count and Ki67 score in the determination of tumor grade and prediction of distant metastasis in well-differentiated pancreatic neuroendocrine tumors. Endocr Pathol 27:162–170. https://doi.org/10.1007/s12022-016-9424-9

    Article  CAS  PubMed  Google Scholar 

  29. Perry A, Stafford SL, Scheithauer BW, Suman VJ, Lohse CM (1998) The prognostic significance of MIB-1, p53, and DNA flow cytometry in completely resected primary meningiomas. Cancer 82:2262–2269. https://doi.org/10.1002/(SICI)1097-0142(19980601)82:11<2262::AID-CNCR23>3.0.CO;2-R

    Article  CAS  PubMed  Google Scholar 

  30. Peyre M, Gauchotte G, Giry M, Froehlich S, Pallud J, Graillon T, Bielle F, Cazals-Hatem D, Varlet P, Figarella-Branger D, Loiseau H, Kalamarides M (2017) De novo and secondary anaplastic meningiomas: a study of clinical and histomolecular prognostic factors. Neuro-Oncology 20:1–9. https://doi.org/10.1093/neuonc/nox231

    Article  CAS  Google Scholar 

  31. Reszec J, Hermanowicz A, Rutkowski R, Turek G, Mariak Z, Chyczewski L (2015) Expression of MMP-9 and VEGF in meningiomas and their correlation with peritumoral brain edema. Biomed Res Int 2015:1–8. https://doi.org/10.1155/2015/646853

    Article  CAS  Google Scholar 

  32. Ribalta T, McCutcheon IE, Aldape KD, Bruner JM, Fuller GN (2004) The mitosis-specific antibody anti-phosphohistone-H3 (PHH3) facilitates rapid reliable grading of meningiomas according to WHO 2000 criteria. Am J Surg Pathol 28:1532–1536. https://doi.org/10.1097/01.pas.0000141389.06925.d5

    Article  PubMed  Google Scholar 

  33. Rogers L, Barani I, Chamberlain M, Kaley TJ, McDermott M, Raizer J, Schiff D, Weber DC, Wen PY, Vogelbaum MA (2015) Meningiomas: knowledge base, treatment outcomes, and uncertainties. A RANO review. J Neurosurg 122:4–23. https://doi.org/10.3171/2014.7.JNS131644

    Article  PubMed  PubMed Central  Google Scholar 

  34. Rosenberg LA, Prayson RA, Lee J, Reddy C, Chao ST, Barnett GH, Vogelbaum MA, Suh JH (2009) Long-term experience with World Health Organization grade III (malignant) meningiomas at a single institution. Int J Radiat Oncol Biol Phys 74:427–432. https://doi.org/10.1016/j.ijrobp.2008.08.018

    Article  PubMed  Google Scholar 

  35. Sahm F, Schrimpf D, Stichel D, Jones DTW, Hielscher T, Schefzyk S, Okonechnikov K, Koelsche C, Reuss DE, Capper D, Sturm D, Wirsching HG, Berghoff AS, Baumgarten P, Kratz A, Huang K, Wefers AK, Hovestadt V, Sill M, Ellis HP, Kurian KM, Okuducu AF, Jungk C, Drueschler K, Schick M, Bewerunge-Hudler M, Mawrin C, Seiz-Rosenhagen M, Ketter R, Simon M, Westphal M, Lamszus K, Becker A, Koch A, Schittenhelm J, Rushing EJ, Collins VP, Brehmer S, Chavez L, Platten M, Hänggi D, Unterberg A, Paulus W, Wick W, Pfister SM, Mittelbronn M, Preusser M, Herold-Mende C, Weller M, von Deimling A (2017) DNA methylation-based classification and grading system for meningioma: a multicentre, retrospective analysis. Lancet Oncol 18:682–694. https://doi.org/10.1016/S1470-2045(17)30155-9

    Article  CAS  PubMed  Google Scholar 

  36. Shan B, Zhang J, Song Y, Xu J (2017) Prognostic factors for patients with World Health Organization grade III meningiomas treated at a single center. Medicine (Baltimore) 96:e7385. https://doi.org/10.1097/MD.0000000000007385

    Article  Google Scholar 

  37. Sughrue ME, Sanai N, Shangari G, Parsa AT, Berger MS, McDermott MW (2010) Outcome and survival following primary and repeat surgery for World Health Organization grade III meningiomas. J Neurosurg 113:202–209. https://doi.org/10.3171/2010.1.JNS091114

    Article  PubMed  Google Scholar 

  38. Winther TL, Arnli MB, Salvesen Ø, Torp SH (2016) Phosphohistone-H3 proliferation index is superior to mitotic index and MIB-1 expression as a predictor of recurrence in human meningiomas. Am J Clin Pathol 146:510–520. https://doi.org/10.1093/ajcp/aqw141

    Article  CAS  PubMed  Google Scholar 

  39. Yang SY, Park CK, Park SH, Kim DG, Chung YS, Jung HW (2008) Atypical and anaplastic meningiomas: prognostic implications of clinicopathological features. J Neurol Neurosurg Psychiatry 79:574–580. https://doi.org/10.1136/jnnp.2007.121582

    Article  PubMed  Google Scholar 

  40. Yuzawa S, Nishihara H, Tanaka S (2016) Genetic landscape of meningioma. Brain Tumor Pathol 33:237–247. https://doi.org/10.1007/s10014-016-0271-7

    Article  CAS  PubMed  Google Scholar 

  41. Zhang G-J, Zhang G-B, Zhang Y-S, Li H, Li C-B, Zhang L-W, Li D, Wu Z, Zhang J-T (2018) WHO grade III (non-anaplastic) meningioma: our experience in a series of 23 cases. World Neurosurg 112:e754–e762. https://doi.org/10.1016/j.wneu.2018.01.149

    Article  PubMed  Google Scholar 

  42. Zhang G-J, Zhang Y-S, Zhang G-B, Da L, Zhang L-W, Wu Z, Zhang J-T (2018) Prognostic factors and the management of anaplastic meningioma. Clin Neurol Neurosurg 170:13–19. https://doi.org/10.1016/j.clineuro.2018.03.028

    Article  PubMed  Google Scholar 

  43. Zhang GJ, Zhang GB, Zhang YS, Li H, Li CB, Zhang LW, Li D, Wu Z, Zhang JT (2018) World Health Organization grade III (nonanaplastic) meningioma: experience in a series of 23 cases. World Neurosurg 112:e754–e762. https://doi.org/10.1016/j.wneu.2018.01.149

    Article  PubMed  Google Scholar 

  44. Zhao P, Hu M, Zhao M, Ren X, Jiang Z (2015) Prognostic factors for patients with atypical or malignant meningiomas treated at a single center. Neurosurg Rev 38:101–107. https://doi.org/10.1007/s10143-014-0558-2

    Article  PubMed  Google Scholar 

Download references

Funding

This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

Author information

Authors and Affiliations

  1. Department of Neurosurgery, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark

    Andrea D. Maier, Jiri Bartek Jr & Marianne Juhler

  2. Department of Neurosurgery, Karolinska University Hospital, Stockholm, Sweden

    Jiri Bartek Jr

  3. Department of Clinical Neuroscience and Department of Medicine, Karolinska Institutet, Stockholm, Sweden

    Jiri Bartek Jr & Tiit I. Mathiesen

  4. Section of Biostatistics, Department of Public Health, University of Copenhagen, Copenhagen, Denmark

    Frank Eriksson

  5. Department of Pathology, Center of Diagnostic Investigation, Copenhagen University Hospital, Copenhagen, Denmark

    Heidi Ugleholdt & Helle Broholm

  6. Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark

    Tiit I. Mathiesen

Authors
  1. Andrea D. Maier
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jiri Bartek Jr
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Frank Eriksson
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Heidi Ugleholdt
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Marianne Juhler
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Helle Broholm
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Tiit I. Mathiesen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Andrea D. Maier.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

This study was approved by the Danish Ethical Committee (approval number H-6-2014-010).

Informed consent

The ethical approval granted waiver of informed consent, as the project does not inflict any additional potential health risks to these patients, besides those which they already have been exposed to and are familiar with, in relation to the diagnostic and the therapeutic treatment. Patients who beforehand had denied the use of their leftover diagnostic material in research were not included, but there were no such requests among the cases of interest.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Maier, A.D., Bartek, J., Eriksson, F. et al. Clinical and histopathological predictors of outcome in malignant meningioma. Neurosurg Rev 43, 643–653 (2020). https://doi.org/10.1007/s10143-019-01093-5

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10143-019-01093-5

Keywords

Search

Navigation